against imatinib-resistant chronic myeloid leukemia. Chronic lymphocytic leukemia (CLL) cells are preferentially activated in so-called proliferation centers frequently found in lymph nodes and bone marrow from CLL patients. 1 In these 'privileged' sites leukemic cells establish close contact with a variety of cell types that provide long-term support for their survival and progression. In addition, CLL cells favor the establishment of immunosuppressive microenvironments by altering the cytokine milieu.
2 Galectin 1 (Gal1), an endogenous b-galactoside-binding lectin found at sites of inflammation and tumor growth, displays pro-survival activity on malignant cells as demonstrated for CD45RA( À ) primary myeloma cells. 3 Moreover, it controls tumor cell proliferation and invasiveness and has key roles in tumor-immune escape by dampening T-cell-mediated immunity. 4 In Hodgkin lymphoma, Gal1 is overexpressed in ReedSternberg cells, which is a predictive biomarker of disease progression and is responsible for creating the Th2/regulatory T-cell-skewed microenvironment typical of this lymphoproliferative disease. 5 These unique characteristics of Gal1 prompted us to investigate its potential role in CLL biology.
We first assessed the expression of Gal1 in peripheral blood and bone marrow samples from CLL patients using quantitative reverse transcriptase-PCR, flow cytometry and immunohistochemistry. We found that monocytes in peripheral blood (Figures 1a and b ) and stromal and myeloid cells in bone marrow biopsies (Figure 1c ) are the main sources of Gal1. CLL cells do not express Gal1, but they are able to bind Gal1 in a dose-dependent manner (Figure 1d ). This effect was glycan-specific, as addition of the disaccharide lactose, but not sucrose inhibited binding of Gal1 to CLL cells (Figure 1d ).
In the presence of leukemic cells, monocytes from CLL patients can differentiate in vitro into large, adherent cells that protect the leukemic clone from spontaneous and drug-induced apoptosis.
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These so-called nurse-like cells (NLC) reside in lymphoid tissues where they presumably deliver pro-survival and stimulating signals to CLL cells. 6 To determine whether Gal1 secreted by myeloid cells can influence leukemic B-cells responses, we knocked down Gal1 synthesis in NLC. For this purpose, we differentiated NLC from peripheral blood CLL samples as previously described, 7 removed non-adherent cells (490% leukemic B cells) and transduced adherent NLC with retrovirus expressing Gal1-specific short hairpin RNA (shRNA) or a scrambled control shRNA (Figures 1e and f) . After 6 h of incubation, transduced NLC were thoroughly washed and non-adherent cells were incorporated to the plates for further co-culture. Thereafter, we evaluated in the leukemic clone expression of the activation markers CD80, CD86 and CD25, production of IL-10 as a prototypical anti-inflammatory cytokine and synthesis of CCL3 and CCL4 as key chemokines responsible for the recruitment of Letters to the Editor monocytes and T lymphocytes to lymphoid tissues. We found that blockade of Gal1 in NLC impaired the expression of activation markers in CLL cells, suggesting that the presence of endogenous Gal1 in myeloid cells is required for full stimulation of the leukemic clone (Supplementary Figure S1) . Blockade of Gal1 also decreased mRNA and protein levels of IL-10 and mRNA levels of CCL3 in CLL cells, without affecting those of CCL4 (Figures 1g and h) . Although previous reports showed that recombinant Gal1 induces the release of IL-10 from activated T lymphocytes and dendritic cells, 8 there is still no information on its effects on CCL3. Of note, both IL-10 and CCL3, are relevant in CLL pathogenesis as their serum concentrations are elevated in CLL patients 9, 10 and, more importantly, they correlate with shorter time-to-first treatment and survival.
11
As B-cell receptor (BCR) signaling has a central role in the survival, proliferation and trafficking of CLL cells, 12 we evaluated whether Gal1 can modulate this pathway. We found that, in the presence of Gal1, suboptimal concentrations of anti-IgM can fully activate the BCR signaling in CLL cells, as assessed by Syk and Erk1/2 phosphorylation (Figure 1i ), indicating that Gal1 may decrease the threshold of BCR activation probably through the formation of lattices as previously suggested for the pre-BCR synapse formation and other receptorligand systems. 4, 13 Although these results indicate that Gal1 secreted by NLC may exert a direct effect on the leukemic clone, we also found that knocking down Gal1 diminished the expression of BAFF and APRIL in NLC (Figure 1j ). Although not evaluated in leukemic cells, BAFF is able to enhance CD86 and induce the secretion of IL-10 in resting B cells.
14 Hence, Gal1 secreted by NLC might directly or indirectly influence CLL activity through glycan-dependent binding to these cells and modulation of BCR signaling or through the control of BAFF and/or APRIL secretion.
Next, we determined the concentration of Gal1 in plasma from 49 CLL samples and 40 age-matched healthy donors. Clinical features of CLL patients are depicted in Supplementary Table S1 . Plasma concentrations of Gal1 were significantly increased in CLL patients compared with healthy subjects (Figure 2a ; Po0.0001). When we discriminated CLL patients in high-and low-risk groups according to the expression of CD38 and ZAP70 on CLL cells, we observed a trend (although not statistically significant) to increased levels of Gal1 in plasma from patients expressing one or both prognostic markers compared with the double-negative group (Figure 2b) . Similarly, we observed that patients in Binet A staging had about half the concentration of Gal1 in plasma compared with patients in Binet C (208 vs 517 ng/ml, n ¼ 25 vs 7). Finally, we analyzed the expression of Gal1 in bone marrow biopsies from patients with stable and progressive disease. We found both an increased number of cells expressing Gal1 and a higher expression of this lectin in bone marrow samples from patients with progressive disease (Figure 2c and e) . In agreement with previous reports, 15 we also observed increased numbers of CD68 þ cells in samples from patients with progressive disease (Figure 2d and e) . These data indicate that Gal1 is associated with poor outcome in CLL.
Collectively, our findings suggest that Gal1 secreted by accompanying myeloid cells (that is, NLC, macrophages and dendritic cells) contributes to stimulate the activity of CLL cells and may help to establish the appropriate microenvironmental conditions for leukemic progression. From a therapeutic standpoint, our study suggests that selective manipulation of Gal1 expression in NLC may be able to influence CLL differentiation and survival, a critical effect with implications in the design of novel antileukemic therapies.
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